<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03654651</url>
  </required_header>
  <id_info>
    <org_study_id>use PKE_PEANUT</org_study_id>
    <nct_id>NCT03654651</nct_id>
  </id_info>
  <brief_title>Peanuts and Glycemic Control</brief_title>
  <official_title>The Role of the Microbiome in Blood Glucose Regulation in Response to Peanut Consumption</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Penn State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Peanut Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Penn State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A two-period randomized crossover study will be conducted to determine the effect of peanuts
      on glycemic control, and elucidate the role of the microbiome in glucose regulation, in
      individuals with impaired fasting glucose.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A two-period randomized crossover trial will be conducted. Participants will be randomized to
      receive each treatment for 6 weeks followed by a minimum 4-week wash-out period. During the
      peanut treatment, participants will consume one ounce per day (28 g) of peanuts as an evening
      snack. The control treatments will be an isocaloric higher carbohydrate snack consumed after
      the evening meal. Markers of glycemic control, cardiovascular risk factors and gut health
      will be assessed at the beginning and the end of each treatment period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Actual">December 20, 2019</completion_date>
  <primary_completion_date type="Actual">December 20, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fasting plasma glucose</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fructosamine</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fasting insulin</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral systolic and diastolic blood pressure</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central systolic and diastolic blood pressure</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Carotid femoral pulse wave velocity</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Augmentation Index (%)</measure>
    <time_frame>6 weeks</time_frame>
    <description>A measure of arterial stiffness assessed using a SphymoCor Ecel (Atcor Medical). A higher percentage value is indicative of greater arterial stiffness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL cholesterol</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL cholesterol</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total cholesterol</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the composition of the gut microbiome</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Type2 Diabetes</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Evening Peanut Consumption</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will consume one ounce per day (28 g) of peanuts as an evening snack (i.e., after dinner and before sleep).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Evening Snack</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will consume an isocaloric higher carbohydrate snack as an evening snack (i.e., after dinner and before sleep).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peanut</intervention_name>
    <description>Roasted, unsalted peanuts will be purchased from a local grocery store and provided to subjects to consume.</description>
    <arm_group_label>Evening Peanut Consumption</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High carbohydrate snack</intervention_name>
    <description>Whole wheat crackers will be purchased from a local grocery store and provided to subjects to consume with a spread (e.g. cream cheese or margarine).</description>
    <arm_group_label>Evening Snack</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non-smoking

          -  Impaired fasting glucose at screening (≥ 100 mg/dL).

          -  BMI ≥20 and ≤40 kg/m2.

        Exclusion Criteria:

          -  Diagnosed diabetes or fasting glucose &gt;126 mg/dl

          -  Systolic blood pressure &gt;160mmHg or diastolic blood pressure &gt;100mmHg)

          -  Prescribed anti-hypertensive, lipid lowering or glucose lowering drugs

          -  Established cardiovascular disease, stroke, diabetes, liver, kidney or autoimmune
             disease or inflammatory conditions

          -  Use of supplements (psyllium, fish oil, soy lecithin, phytoestrogens) and botanicals
             and not willing to cease for the duration of the study

          -  Pregnancy or lactation

          -  Weight loss of &gt;=10% of body weight within the 6 months prior to enrolling in the
             study

          -  Smoking or use of any tobacco products

          -  Allergy to test foods

          -  Consumption of &gt;14 alcoholic drinks/week
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Penny M Kris-Etherton, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Penn State University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kristina S Petersen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Penn State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pennsylvania State University</name>
      <address>
        <city>University Park</city>
        <state>Pennsylvania</state>
        <zip>16802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>August 29, 2018</study_first_submitted>
  <study_first_submitted_qc>August 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2018</study_first_posted>
  <last_update_submitted>February 18, 2020</last_update_submitted>
  <last_update_submitted_qc>February 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Penn State University</investigator_affiliation>
    <investigator_full_name>Penny</investigator_full_name>
    <investigator_title>Distinguished Professor of Nutrition</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

